UTHRNasdaqPharmaceutical PreparationsFiscal year ends December 31
UNITED THERAPEUTICS Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$543.15+10.03 (+1.88%)
Close on Oct 19, 2026
- Market cap
- $24.88B
- P/E (TTM)
- 19.4
- Dividend yield
- –
Share price
+$109.81 (+25.34%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
UNITED THERAPEUTICS Corp grew revenue 2.5% to $3.15B over the twelve months to Jun 30, 2026. Operating income fell 3.2% to $1.40B, moving the operating margin from 47.0% to 44.4%. Free cash flow was $1.09B, up 2.1% from a year earlier.
Revenue
$3.15B
+2.5% vs. a year earlier
Operating income
$1.40B
-3.2% vs. a year earlier
Free cash flow
$1.09B
+2.1% vs. a year earlier
EPS, diluted
$27.95
+9.0% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $24.88B
- P/E ratio
- 19.4
- Price to sales
- 7.89
- Price to book
- 3.89
- Dividend yield
- –
- Free cash flow yield
- 4.39%
Fundamentals
- Revenue
- $3.15B
- Net income
- $1.31B
- EPS, diluted
- $27.95
- Free cash flow
- $1.09B
- Book value per share
- $139.74
- Diluted shares
- 46M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$3.15B+2.5% YoY
Gross profit
$2.72B-0.8% YoY
Operating income
$1.40B-3.2% YoY
Net income
$1.31B+5.5% YoY
EPS, diluted
$27.95+9.0% YoY
Free cash flow
$1.09B+2.1% YoY
Reported periodTrailing twelve months